DETAILED ACTION
Notice of Pre-AIA or AIA Status
The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA .
Claim Rejections - 35 USC § 102
In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis (i.e., changing from AIA to pre-AIA ) for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status.
The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:
A person shall be entitled to a patent unless –
(a)(1) the claimed invention was patented, described in a printed publication, or in public use, on sale, or otherwise available to the public before the effective filing date of the claimed invention.
Claim 12 is rejected under 35 U.S.C. 102(a)(1) as being anticipated by Sershon et al. (US 2021/0212348 A1; July 15, 2021).
Regarding claim 12, Sershon discloses a fermented dairy product analogue ([0022], [0024]) comprising hydrophilic liquid (e.g. water, [0010], [0024]), at least one non-dairy ingredient comprising beta-glucans that is a plant ingredient ([0021]), and ascorbic acid ([0107]).
Claim Rejections - 35 USC § 103
In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis (i.e., changing from AIA to pre-AIA ) for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status.
The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action:
A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made.
The factual inquiries for establishing a background for determining obviousness under 35 U.S.C. 103 are summarized as follows:
1. Determining the scope and contents of the prior art.
2. Ascertaining the differences between the prior art and the claims at issue.
3. Resolving the level of ordinary skill in the pertinent art.
4. Considering objective evidence present in the application indicating obviousness or nonobviousness.
This application currently names joint inventors. In considering patentability of the claims the examiner presumes that the subject matter of the various claims was commonly owned as of the effective filing date of the claimed invention(s) absent any evidence to the contrary. Applicant is advised of the obligation under 37 CFR 1.56 to point out the inventor and effective filing dates of each claim that was not commonly owned as of the effective filing date of the later invention in order for the examiner to consider the applicability of 35 U.S.C. 102(b)(2)(C) for any potential 35 U.S.C. 102(a)(2) prior art against the later invention.
Claims 1-11, 14 and 16 are rejected under 35 U.S.C. 103 as being unpatentable over Sershon et al. (US 2021/0212348 A1; July 15, 2021).
Regarding claim 1, Sershon discloses a method for preparing a fermented dairy analogue comprising:
Providing an edible suspension comprising a hydrophilic liquid, e.g. water, and at least one non-dairy ingredient, wherein the non-dairy ingredient comprises beta-glucans and is a plant ingredient ([0021]-[0024], [0113]),
Adding ascorbic acid as additional ingredient ([0107], [0113]),
Homogenizing the edible suspension ([0114]),
Heat-treating the edible suspension ([0024], [0115]),
Inoculating the homogenized and heat-treated edible suspension with a starter culture ([0024], [0117]),
Fermenting the inoculated edible suspension until reaching a pH of less than about 4.6 to obtain a fermented dairy analogue ([0024], [0118]), which falls within the claimed pH range of less than 5.0.
The examiner notes that ascorbic acid is listed under additional ingredients as a non-mineral nutritional supplement ([0101]-[0107]), which can be added to the edible suspension before homogenizing ([0113] as “additional ingredients”), but is not specifically added in the claimed process. However, it would have been obvious to one of ordinary skill in the art to add ascorbic acid to the edible suspension as one of the additional ingredients depending on the desired nutritional supplementation.
Regarding claim 2, Sershon teaches that the non-dairy ingredient comprises at least about 3-5% by weight beta glucan ([0048]), thus falling within the claimed range of at least 0.5 wt%.
Regarding claims 3-5, Sershon teaches that the non-dairy ingredient is a cereal flour originated from oat ([0048]).
Regarding claim 6, Sershon teaches that the edible suspension comprises about 1% to about 15% by weight oat flour ([0063]-[0066]), or the non-dairy ingredient, thus falling within the claimed range of 1-15%.
Regarding claim 7, Sershon further teaches that the ascorbic acid can be present in an amount from 0.1 to 2% by weight ([0107]-[0108]), thus falling within the claimed range of at least 0.01 wt%.
Regarding claims 8-10, Sershon teaches that the edible suspension comprising the ascorbic acid can further include at least one plant protein ingredient that is different from the non-dairy ingredient, wherein the plant protein is a pea protein isolate ([0016]).
Regarding claim 11, as stated above with respect to claim 1, Sershon teaches adding ascorbic acid as an additiona ingredient. Sershon teaches that the ingredients are mixed for a time suitable to hydrate the whole grain ingredient and to thoroughly blend all the ingredients to form a final mixture, wherein the time is about 30 minutes ([0113]). Therefore, Sershon teaches that the ascorbic acid is added at least 20 minutes before the heat treatment as the ingredients are mixed together for 30 minutes.
Regarding claim 14, Sershon discloses a method for preparing a fermented dairy analogue comprising adding ascorbic acid as additional ingredient to an edible suspension before fermentation with a starter culture([0107], [0113]), wherein the edible suspension comprises a hydrophilic liquid, e.g. water, and at least one non-dairy ingredient, wherein the non-dairy ingredient comprises beta-glucans and is a plant ingredient ([0021]-[0024], [0113]),
The examiner notes that ascorbic acid is listed under additional ingredients as a non-mineral nutritional supplement ([0101]-[0107]), which can be added to the edible suspension before fermentation ([0113] as “additional ingredients”), but is not specifically added in the claimed process. However, it would have been obvious to one of ordinary skill in the art to add ascorbic acid to the edible suspension as one of the additional ingredients depending on the desired nutritional supplementation.
With respect to the method reducing the adhesiveness of a fermented dairy product analogue, Sershon fails to specifically teach such property, however, as Sershon teaches a fermented dairy product comprising the same ingredients as claimed, including the addition of ascorbic acid, the method would necessarily and inherently reduce the adhesiveness of the fermented dairy product.
As stated in In re Best, 562 F.2d 1252, 1255 (CCPA 1977): Where, as here, the claimed and prior art products are identical or substantially identical, or are produced by identical or substantially identical processes, the PTO can require an applicant to prove that the prior art products do not necessarily or inherently possess the characteristics of his claimed product. Whether the rejection is based on "inherency" under 35 U.S.C. § 102, on “prima facie obviousness” under 35 U.S.C. § 103, jointly or alternatively, the burden of proof is the same, and its fairness is evidenced by the PTO’s inability to manufacture products or to obtain and compare prior art products.
Regarding claim 16, as stated above, Sershon fails to specifically teach measuring adhesiveness, however, it would have been obvious to measure it by any known means in the art using desired parameters. It would have been obvious to vary the parameters for measuring the adhesiveness depending on the type of measurement desired. This is merely routine experimentation that is well within the ordinary skill in the art.
Conclusion
No claims are allowed.
Any inquiry concerning this communication or earlier communications from the examiner should be directed to STEPHANIE A KOHLER whose telephone number is (571)270-1075. The examiner can normally be reached Monday-Friday 8am-5pm.
Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice.
If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Nikki Dees can be reached at (571) 270-3435. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.
Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.
/STEPHANIE A KOHLER/Primary Examiner, Art Unit 1791